Hi All,
Now reseachers have found that increased expression of BCL2L10 is linked to Vidaza resistance. Overexpression of this gene has been shown to suppress cell apoptosis (programmed cell death).
Perhaps they now will start looking at the gene BCL2L10 before they start Vidaza treatment in the same way as they look for the chromosome aberration del5q before they start treatment with Revlimid.
http://www.ncbi.nlm.nih.gov/pubmed/22577154
Kind regards
Birgitta-A